WaveMan
WaveMan · Company
INDP · Indaptus Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

INDP Indaptus Therapeutics (INDP) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001857044
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
8
13F, latest reported quarter

INDP filings, in plain words

Read the full summary

The latest 5% ownership filing is a 13D by Yao Yun, filed 2026-03-30, for 37.8% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Indaptus Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Indaptus Therapeutics, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Anderson Glen R.
BUY
2023-08-16 SECtraded 2023-08-14
23,934
$56.0K
-95.0%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Aug 11, 2023.
  • +8.0% median (+8.0% mean) 90-day return after 2 previous buys.
  • The trade is 2.0% of the 1,190,400 shares held after it.
  • No other insider bought within 30 days.
  • 8 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Anderson Glen R. bought about $56.0K of INDP on Aug 14, 2023; 8 funds added in the latest 13F quarter.
Anderson Glen R.
BUY
2023-08-16 SECtraded 2023-08-11
35,064
$74.3K
-95.0%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Aug 10, 2023.
  • The trade is 3.0% of the 1,166,466 shares held after it.
  • No other insider bought within 30 days.
  • 8 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Anderson Glen R. bought about $74.3K of INDP on Aug 11, 2023; 8 funds added in the latest 13F quarter.
Anderson Glen R.
BUY
2023-08-16 SECtraded 2023-08-10
44,354
$86.0K
-95.0%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 3.9% of the 1,131,402 shares held after it.
  • No other insider bought within 30 days.
  • 8 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Anderson Glen R. bought about $86.0K of INDP on Aug 10, 2023, the largest insider purchase at the company on our record; 8 funds added in the latest 13F quarter.
Litchev Boyan Vesselinov
Chief Medical Officer
BUY
2022-12-19 SECtraded 2022-12-01
500
$935
-92.8%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Nov 22, 2022.
  • -37.9% median (-26.4% mean) 90-day return after 3 previous buys.
  • The trade is 43.5% of the 1,150 shares held after it.
  • 1 other insider bought within 30 days.
  • 8 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Litchev Boyan Vesselinov bought about $935 of INDP on Dec 1, 2022; 1 other insider bought within 30 days and 8 funds added in the latest 13F quarter.
Litchev Boyan Vesselinov
Chief Medical Officer
BUY
2022-12-19 SECtraded 2022-11-22
500
$915
-92.8%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Mar 2, 2022.
  • -37.9% median (-37.9% mean) 90-day return after 2 previous buys.
  • The trade is 76.9% of the 650 shares held after it.
  • 1 other insider bought within 30 days.
  • 8 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Litchev Boyan Vesselinov bought about $915 of INDP on Nov 22, 2022; 1 other insider bought within 30 days and 8 funds added in the latest 13F quarter.
18 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 13 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
8 funds bought in last quarter
below 89% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
2.1% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
below 78% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch INDP

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-5.9%12M
-74%-38%-2%+34%2025-102025-122026-022026-042026-062026-082026-10 2026-03-30 · Yao Yun filed a 5%+ stake (37.8%)2026-03-30 · SINO LION VENTURES Ltd filed a 5%+ stake (35.0%)2026-03-30 · Xu Chenhao filed a 5%+ stake (35.0%)2026-03-30 · Dai Junyi filed a 5%+ stake (10.1%)2026-03-30 · Yang Ting filed a 5%+ stake (10.1%)2026-03-30 · Deng Lina filed a 5%+ stake (5.0%)2026-03-02 · Lazar David E. filed a 5%+ stake (98.0%)
13D/G stake
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns INDP: institutional holders (13F)

13F holdings, latest reported quarter
GEODE CAPITAL MANAGEMENT, LLC
56,470 sh
$169.4K
JANE STREET GROUP, LLC
53,811 sh
$161.4K
VANGUARD CAPITAL MANAGEMENT LLC
33,652 sh
$101.0K
VANGUARD FIDUCIARY TRUST CO
13,967 sh
$41.9K
MILLENNIUM MANAGEMENT LLC
11,586 sh
$34.8K

Congress trades in INDP

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive
Yao Yun
Activist 13D · 2026-03-30
37.8%
SINO LION VENTURES Ltd
Activist 13D · 2026-03-30
35.0%
Xu Chenhao
Activist 13D · 2026-03-30
35.0%
Dai Junyi
Activist 13D · 2026-03-30
10.1%
Yang Ting
Activist 13D · 2026-03-30
10.1%

INDP planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

INDP mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$31.0K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$27.4K position · as of 2026-06-30
0.0%
Fidelity Series Total Market Index Fund
$6.9K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$813 position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
1 registered trials, 1 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Multi-phase
1 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · Jeffrey A. Meckler
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$2.2M
$2.1M
$1.8M
-88%
n/a
2024
$1.2M
$1.0M
$949.6K
-52%
n/a
2023
$1.0M
$1.1M
$744.0K
+21%
n/a
2022
$1.7M
-$38.4K
$1.1M
-75%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 8 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

INDP financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-318.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-163.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-193.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$19.8M-$15.4M-$16.4M-$14.9M
Net income-$20.8M-$15.0M-$15.4M-$14.3M
EPS (diluted)-21.58-44.96-1.83-1.73
Operating cash flow-$14.8M-$12.3M-$13.4M-$13.1M
Cash$8.5M$5.8M$13.4M$9.6M
SEC XBRL, fiscal years, as known on 2026-10-28

INDP Stock Sonar score 3/7 axes

Find similar shapesCompare

INDP ranks highest on risk and compliance (74th percentile) and profitability (12th), and lowest on institutional and government (11th), among Pharma & Biotech peers.

Profitability
12
Inputs
  • Return on equity-318.0% · 12 pct, sector of 545
  • Return on assets-163.8% · 14 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-193.3% · 10 pct, sector of 576
Institutional and government
11
Inputs
  • Funds adding, latest quarter8 · 11 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
74
Inputs
  • Short interest, % of float+2.1% · 74 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
4 not measured: Financial health, Growth, Insider conviction, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies